ArticleFrontiers in pharmacology2026
Cost-effectiveness analysis of pyrotinib combined with trastuzumab and docetaxel as first-line treatment for HER2-positive metastatic breast cancer in China.
Miao Liang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.